News

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical Research Act.
(HealthDay News) — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION), according ...
In this cohort study of individuals with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use was ...
Over time, these drugs have also been found to help people lose weight by slowing digestion, reducing hunger, and making ...
A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...
A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured.
Americans are flocking to new weight loss medications like Novo Nordisk’s Wegovy and Eli Lilly's Zepbound, which work by ...
Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 ...
A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...
GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...
Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...